Sirtuin Proteins and Memory: A Promising Target in Alzheimer’s Disease Therapy? DOI Open Access
Francesca Fernandez, Lyn R. Griffiths, Heidi G. Sutherland

и другие.

Nutrients, Год журнала: 2024, Номер 16(23), С. 4088 - 4088

Опубликована: Ноя. 27, 2024

Sirtuins (SIRTs), nicotine adenine dinucleotide (+)-dependent histone deacetylases, have emerged as critical regulators in many signalling pathways involved a wide range of biological processes. Currently, seven mammalian SIRTs been characterized and are found across number cellular compartments. There has considerable interest the role brain due to their plethora metabolic- age-related diseases, including involvement learning memory function physiological pathophysiological conditions. Although cognitive declines over course healthy ageing, neurological disorders Alzheimer's disease (AD) can be associated with progressive impairments. This review aimed report integrate recent advances understanding dysfunction context AD. We also reviewed use selective and/or natural SIRT activators potential therapeutic agents adjuvants for

Язык: Английский

ROS-related nanoparticles for the management of Alzheimer’s disease: Wielding the double-edged sword DOI

Yibin Yu,

Qi Zhang, Yihao Guo

и другие.

Chemical Engineering Journal, Год журнала: 2025, Номер unknown, С. 161784 - 161784

Опубликована: Март 1, 2025

Язык: Английский

Процитировано

0
Disease Modifying Monoclonal Antibodies and Symptomatic Pharmacological Treatment for Alzheimer’s Disease DOI Creative Commons
Xiaoming Qi, Damir Nizamutdinov, Sheng‐Han Yi

и другие.

Biomedicines, Год журнала: 2024, Номер 12(11), С. 2636 - 2636

Опубликована: Ноя. 19, 2024

Alzheimer's Disease (AD) is an irreversible, progressive syndrome characterized by neurocognitive impairment. Two neuropathological features seen in AD are extracellular amyloid plaques consisting of beta1-40 and 1-42, intracellular neurofibrillary tangles (NFTs). For decades, neuroscience research has heavily focused on seeking to understand the primary mechanism searching for pharmacological approaches treatment dementia. Three monoclonal antibodies that act against beta-aducanumab, lecanemab, donanemab-have been approved Food Drug Administration (FDA) mild cognitive impairment AD, addition medications symptom management such as acetylcholinesterase inhibitors N-methyl-D-aspartate (NMDA) antagonist. Further trials should focus combination therapies targeting tau pathology.

Язык: Английский

Процитировано

3
Sirtuin Proteins and Memory: A Promising Target in Alzheimer’s Disease Therapy? DOI Open Access
Francesca Fernandez, Lyn R. Griffiths, Heidi G. Sutherland

и другие.

Nutrients, Год журнала: 2024, Номер 16(23), С. 4088 - 4088

Опубликована: Ноя. 27, 2024

Sirtuins (SIRTs), nicotine adenine dinucleotide (+)-dependent histone deacetylases, have emerged as critical regulators in many signalling pathways involved a wide range of biological processes. Currently, seven mammalian SIRTs been characterized and are found across number cellular compartments. There has considerable interest the role brain due to their plethora metabolic- age-related diseases, including involvement learning memory function physiological pathophysiological conditions. Although cognitive declines over course healthy ageing, neurological disorders Alzheimer's disease (AD) can be associated with progressive impairments. This review aimed report integrate recent advances understanding dysfunction context AD. We also reviewed use selective and/or natural SIRT activators potential therapeutic agents adjuvants for

Язык: Английский

Процитировано

0